Tumour cells resistance in cancer therapy

Clinical and Translational Oncology

Volumn 9, Issue 1, 2007, Pages 13-20

  Martínez Lacaci, Isabel ^a   GarcÍa Morales, Pilar ^b   Soto, JosÉ Luis ^b   Saceda, Miguel ^b  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

Apoptosis; Chemoresistance; MDR

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; GEFITINIB; IRINOTECAN; METHOTREXATE; PLATINUM COMPLEX; RALTITREXED; SOMATOMEDIN C; VANDETANIB;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL DEATH; COLORECTAL CANCER; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; DRUG METABOLISM; DRUG SENSITIVITY; DRUG TARGETING; DRUG TRANSPORT; DRUG TREATMENT FAILURE; HUMAN; MICROENVIRONMENT; MOLECULAR DYNAMICS; PLEIOTROPY; PROGNOSIS; TUMOR RESISTANCE; ANIMAL; DRUG RESISTANCE; NEOPLASM; PATHOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; CELL DEATH; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34249021632     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0004-9     Document Type: Article

References (91)

1. Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205:275-292
2. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48-58
3. Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6:583-592
4. Denekamp J Hobson B (1982) Endothelial-cell proliferation in experimental tumours. Br J Cancer 46:711-720
5. Brown JM, Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4:437-447
6. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891-899
7. Raghunand N, Gatenby RA, Gillies RJ (2003) Microenvironmental and cellular consequences of altered blood flow in tumours. Br J Radiol 76:S11-S22
8. Dean M, Fojo T Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5:275-284
9. Harris AL (2002) Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2:38-47
10. Jain RK (1999) Understanding barriers to drug delivery: High resolution in vivo imaging is key. Clin Cancer Res 5:1605-1606
11. Green SK, Francia G, Isidoro C, Kerbel RS (2004) Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. Mol Cancer Ther 3:149-159
12. Hazlehurst LA, Damiano JS, Buyuksal I et al (2000) Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 19:4319-4327
13. Weaver VM, Lelievre S, Lakins JN et al (2002) Beta4 integrin-dependent formation of polarized three-dimensional architecture architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2:205-216
14. Damiano JS, Cress AE, Hazlehurst LA et al (1999) Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93:1658-1667
15. Damiano JS, Dalton WS (2000) Integrinmediated drug resistance in multiple myeloma. Leuk Lymphoma 38:71-81
16. LaRue KE, Bradbury EM, Freyer JP (1998) Differential regulation of cyclindependent kinase inhibitors in monolayer and spheroid cultures of tumorigenic and nontumorigenic fibroblasts. Cancer Res 58:1305-1314
17. Mahyar-Roemer M, Roemer K (2001) p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents. Oncogene 20:3387-3398
18. Syrigos KN, Karayiannakis AJ (2006) Adhesion molecules as targets for the treatment of neoplastic diseases. Curr Pharm Des 12:2849-2861
19. Hehlgans S, Haase M, Cordes N (2006) Signalling via integrins: Implications for cell survival and anticancer strategies. Biochim Biophys Acta 1775:163-180
20. Wang F, Hansen RK, Radisky D et al (2002) Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J Natl Cancer Inst 94:1494-1503
21. Weaver VM, Petersen OW, Wang F et al (1997) Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 137:231-245
22. Huang Y, Anderle P, Bussey, KJ et al (2004) Membrane transporters and channels: Role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 64:4294-4301
23. Choudhuri S, Klaassen CD (2006) Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 25:231-259
24. Huang Y, Sadee W (2006) Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Lett 239:168-182
25. Banerjee D, Mayer-Kuckuk P, Capiaux, G et al (2002) Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta 1587:164-173
26. Levy AS, Sather HN, Steinherz PG et al (2003) Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: A Children's Cancer Group Study. J Pediatr Hematol Oncol 25:688-695
27. Costea I, Moghrabi A, Laverdiere C et al (2006) Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica 91:1113-1116
28. Laverdiere C, Chiasson S, Costea I et al (2002) Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 100:3832-3834
29. Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615-627
30. Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215-237
31. Takebe N, Zhao SC, Ural A et al (2001) Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells. Cancer Gene Ther 8:966-973
32. Wernyj RP, Morin PJ (2004) Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resist Updat 7:227-232
33. Cummings J, Boyd G, Ethell BT et al (2002) Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation. Biochem Pharmacol 63:607-613
34. Cummings J, Zelcer N, Allen JD et al (2004) Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins. Biochem Pharmacol 67:31-39
35. Rouits, E., Boisdron-Celle, M Dumont et al (2004) Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: A molecular and clinical study of 75 patients. Clin Cancer Res 10:5151-5159
36. Houghton JA, Houghton PJ (1983) Elucidation of pathways of 5-fluorouracil metabolism in xenografts of human colorectal adenocarcinoma. Eur J Cancer Clin Oncol 19:807-815
37. Xu Y, Villalona-Calero MA (2002) Irinotecan: Mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 13:1841-1851
38. Marsh S, McLeod HL (2001) Thymidylate synthase pharmacogenetics in colorectal cancer. Clin Colorectal Cancer 1:175-178
39. Noguchi S (2006) Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 97:813-820
40. Brabec V, Kasparkova J (2005) Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updat 8:131-146
41. Brown R, Hirst GL, Gallagher WM et al (1997) hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 15:45-52
42. Plumb JA, Finn PW, Williams R. J et al (2003) Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2:721-728
43. Bremer E, van Dam G, Kroesen BJ et al (2006) Targeted induction of apoptosis for cancer therapy: Current progress and prospects. Trends Mol Med 12:382-393
44. Gerl R, Vaux DL (2005) Apoptosis in the development and treatment of cancer. Carcinogenesis 26:263-270
45. Hersey P, Zhang XD (2003) Overcoming resistance of cancer cells to apoptosis. J Cell Physiol 196:9-18
46. Hersey P, Zhuang L, Zhang XD (2006) Current strategies in overcoming resistance of cancer cells to apoptosis melanoma as a model. Int Rev Cytol 251:131-158
47. Okada H, Mak TW (2004) Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 4:592-603
48. Tsuruo T, Naito M, Tomida A et al (2003) Molecular targeting therapy of cancer: Drug resistance, apoptosis and survival signal. Cancer Sci 94:15-21
49. Burlacu A (2003) Regulation of apoptosis by Bcl-2 family proteins. J Cell Mol Med 7:249-257
50. Cory S, Adams JM (2005) Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell 8:5-6
51. Otera H, Ohsakaya S, Nagaura Z et al (2005) Export of mitochondrial AIF in response to proapoptotic stimuli depends on processing at the intermembrane space. EMBO J 24:1375-1386
52. Huang Y, Park YC, Rich RL et al (2001) Structural basis of caspase inhibition by XIAP: Differential roles of the linker versus the BIR domain. Cell 104:781-790
53. Riedl SJ, Renatus M, Schwarzenbacher R et al (2001) Structural basis for the inhibition inhibition of caspase-3 by XIAP. Cell 104:791-800
54. Srinivasula SM, Hegde R, Saleh A et al (2001) A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 410:112-116
55. Sun C, Cai M, Gunasekera AH et al (1999) NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP. Nature 401:818-822
56. Verhagen AM, Coulson E J, Vaux DL (2001) Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol 2:3009
57. Wu G, Chai J, Suber TL et al (2000) Structural basis of IAP recognition by Smac/DIABLO. Nature 408:1008-1012
58. Suzuki H, Motegi M, Akagi T et al (1999) API1-MALT1-MLT is involved in mucosa-associated lymphoid tissue lymphoma with t(11;18)(q21;q21). Blood 94:3270-3271
59. Vaux DL, Cory S, Adams JM (1988) Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440-442
60. Angeloni SV, Martin MB, Garcia-Morales P et al (2004) Regulation of estrogen receptor-alpha expression by the tumor suppressor gene p53 in MCF-7 cells. J Endocrinol 180:497-504
61. Lane DP (1992) Cancer. p53, guardian of the genome. Nature 358:15-16
62. Nakano K, Vousden KH (2001) PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7:683-694
63. Yu J, Zhang L, Hwang PM et al (2001) PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 7:673-682
64. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501
65. Amiri KI, Richmond A (2005) Role of nuclear factor-kappa B in melanoma. Cancer Metastasis Rev 24:301-313
66. Robertson GP (2005) Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev 24:273-285
67. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137
68. Kim ES, Khuri FR, Herbst RS (2001) Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 13:506-513
69. Camp ER, Summy J, Bauer T et al (2005) Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 11:397-405
70. Morgillo F, Lee H (2005) Y. Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist Updat 8:298-310
71. Mendelsohn J (2001) The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 8:3-9
72. Mendelsohn J (2002) Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20:1-13
73. Garcia d. P IE, Adams GP, Sundareshan P et al (1993) Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 53:3217-3220
74. Wikstrand CJ, Reist CJ, Archer GE et al (1998) The class III variant of the epidermal growth factor receptor (EGFRvIII): Characterization and utilization as an immunotherapeutic target. J Neurovirol 4:148-158
75. Learn CA, Hartzell TL, Wikstrand CJ et al (2004) Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 10:3216-3224
76. Li B, Yuan M, Kim IA et al (2004) Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin. Oncogene 23:4594-4602
77. Nagane M, Coufal F, Lin H et al (1996) A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56:5079-5086
78. Nagane M, Levitzki A, Gazit A et al (1998) Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci USA 95:5724-5729
79. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139
80. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500
81. Bancroft CC, Chen Z, Yeh J et al (2002) Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 99:538-548
82. Goldman CK, Kim J, Wong WL et al (1993) Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4:121-133
83. Ciardiello F, Caputo R, Damiano V et al (2003) Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9:1546-1556
84. Viloria-Petit A, Crombet T, Jothy S et al (2001) Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res 61:5090-5101
85. Jones HE, Goddard L, Gee JM et al (2004) Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11:793-814
86. Lu Y, Zi X, Zhao Y et al (2001) Insulinlike growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93:1852-1857
87. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G (2003) Response to epidermal growth factor receptor inhibitors in nonsmall cell lung cancer cells: Limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 9:2316-2326
88. Magne N, Fischel JL, Dubreuil A et al (2002) Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (Iressa). Br J Cancer 86:1518-1523
89. Bianco R, Shin I, Ritter CA et al (2003) Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22:2812-2822
90. Liu D, Aguirre GJ, Estrada Y, Ossowski L (2002) EGFR is a transducer of the urokinase receptor initiated signal that is required required for in vivo growth of a human carcinoma. Cancer Cell 1:445-457
91. Moro L, Dolce L, Cabodi S et al (2002) Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines. J Biol Chem 277:9405-9414